<DOC>
	<DOCNO>NCT00918463</DOCNO>
	<brief_summary>This Phase II , single institution , single-arm , open-label study oral dasatinib monotherapy administer subject relapse refractory aggressive DLBCL . This study conduct two phase : Treatment Phase Follow-up Phase . Research Hypothesis : Dasatinib , administer orally continuous dose 100 mg daily , safe effective treat subject fail prior therapy diffuse large B cell lymphoma ( DLBCL ) relapse disease .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy Dasatinib ( Sprycel ) Subjects With Relapsed Refractory Diffuse Large B-Cell Lymphoma ( DLBCL )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Must understand voluntarily sign informed consent form . Must &gt; = 18 year age time sign informed consent form . Must able adhere study visit schedule protocol requirement . Biopsyproven aggressive Diffuse Large BCell Lymphoma . Relapsed refractory previous therapy lymphoma . Subjects must receive least one prior combination chemotherapy regimen . There limit number prior therapy . Subjects relapse follow autologous stem cell transplant eligible . Subjects must measurable disease cross sectional imaging least 2 cm long diameter . Eastern Cooperative Oncology Group ( ECOG ) performance status score 0 , 1 , 2 . Life expectancy &gt; = 90 day ( 3 month ) . Ability take oral medication : dasatinib tablet may swallow whole . Adequate organ function : Total bilirubin &lt; 2.0 time Upper Limit Normal ( ULN ) Serum Na , K , Mg , Phos , Ca &gt; Lower Limit Normal ( LLN ) Hemoglobin , neutrophil count , platelet , PT/PTT grade 01 Serum creatinine concentration &lt; 1.5 x institutional upper limit normal ( ULN ) . Serum SGOT/AST SGPT/ALT &lt; 2.5 x institutional upper limit normal ( ULN ) . Concomitant medication : 1 . Patient agree discontinue St. Johns Wort receive dasatinib 2 . IV biphosphonates withhold first 8 week dasatinib therapy due risk hypocalcemia . Females childbearing potential ( FCBP ) must agree use two reliable form contraception simultaneously practice complete abstinence heterosexual intercourse follow time period relate study : 1 ) least 28 day start study drug ; 2 ) participate study ; 3 ) least 28 day discontinuation study . The two method reliable contraception must include one highly effective method ( i.e . intrauterine device ( IUD ) , hormonal [ birth control pill , injection , implant ] , tubal ligation , partner 's vasectomy ) one additional effective ( barrier ) method ( i.e . latex condom , diaphragm , cervical cap ) . FCBP must refer qualified provider contraceptive method need . Before start study drug : Female Subjects : FCBP must two negative pregnancy test ( sensitivity least 50 mIU/mL ) prior start study drug . The first pregnancy test must perform within 1014 day prior start study drug second pregnancy test must perform within 24 hour prior start study drug . The subject may receive study drug Investigator verify result pregnancy test negative ; Will warn share study drug prohibit counseled pregnancy precaution potential risk fetal exposure ; Must agree abstain donate blood study participation least 28 day discontinuation study . Male Subjects : Must agree use latex condom sexual contact female childbearing potential participate study least 28 day follow discontinuation study even undergone successful vasectomy ; Will warn share study drug prohibit counseled pregnancy precaution potential risk fetal exposure ; Must agree abstain donate blood , semen , sperm study participation least 28 day discontinuation study . During study participation 28 day follow discontinuation study : All Subjects : No 30day supply study drug dispense time . Female Subjects : FCBP regular cycle must agree pregnancy test weekly first 28 day study participation every 28 day study , study discontinuation , day 28 follow discontinuation study . If menstrual cycle irregular , pregnancy test must occur weekly first 28 day every 14 day study , study discontinuation , day 14 28 follow discontinuation study . In addition require pregnancy test , Investigator must confirm FCBP continue use two reliable method birth control visit . Counseling pregnancy precaution potential risk fetal exposure must conduct minimum every 28 day . During counseling , subject must remind share study drug donate blood . Pregnancy test counsel must perform subject miss period pregnancy test menstrual bleeding abnormal . Study drug treatment must discontinue evaluation . Females must agree abstain breastfeed study participation least 28 day discontinuation study . Male Subjects : Counseling requirement latex condom use sexual contact female childbearing potential potential risk fetal exposure must conduct minimum every 28 day . During counseling , subject must remind share study drug donate blood , sperm , semen . If pregnancy positive pregnancy test occur study subject partner male study subject study participation , study drug must immediately discontinue . Subjects candidate willing undergo autologous stem cell transplant . Subjects post allogeneic stem cell transplant . All subject active central nervous system ( CNS ) lymphoma . Subjects previous CNS lymphoma treat chemotherapy , radiotherapy surgery remain asymptomatic 90 day ( 3 month ) demonstrate , CNS lymphoma , show lumbar puncture , CT scan MRI , eligible . ( If require , lumbar puncture , CT MRI perform screen process . ) Subjects receive corticosteroid . Prior history malignancy NHL ( except basal cell squamous cell carcinoma skin carcinoma situ cervix breast ) unless subject free disease &gt; = 365 day ( 1 year ) . Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form . Known positive HIV . Pregnant lactate female . Concomitant Medications : Category I drug generally accept risk cause Torsades de Pointes include : ( Patients must discontinue drug 7 day prior start dasatinib ) quinidine , procainamide , disopyramide , amiodarone , sotalol , ibutilide , dofetilide , erythromycin , clarithromycin , chlorpromazine , haloperidol , mesoridazine , thioridazine , pimozide , cisapride , bepridil , droperidol , methadone , arsenic , chloroquine , domperidone , halofantrine , levomethadyl , pentamidine , sparfloxacin , lidoflazine Concurrent medical condition may increase risk toxicity , include : 1 . Pericardial pleural effusion grade 2 . Clinicallysignificant coagulation platelet function disorder ( e.g . know von Willebrand 's disease ) History significant bleeding disorder unrelated cancer , include : 1 . Diagnosed congenital bleeding disorder ( e.g. , von Willebrand 's disease ) 2 . Diagnosed acquire bleed disorder within one year ( e.g. , acquire antifactor VIII antibody ) 3 . Ongoing recent ( &lt; = 3 month ) clinically significant gastrointestinal bleeding Cardiac symptom within 6 month : 1 . Uncontrolled angina , congestive heart failure , MI 2 . History clinically significant ventricular arrythmias : fibrillation , Torsades de pointes , tachycardia . 3 . Prolonged QTc interval preentry electrocardiogram ( &gt; 450msec ) . Prior use dasatinib . Use standard experimental anticancer drug therapy within 28 day initiation ( Day 1 ) study drug therapy . Known active Hepatitis B C. Prisoners subject compulsorily detain ( involuntarily incarcerate ) treatment either psychiatric physical ( e.g. , infectious ) illness .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>lymphoma</keyword>
	<keyword>diffuse</keyword>
	<keyword>refractory</keyword>
</DOC>